{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T21:59:45Z","timestamp":1761947985115,"version":"build-2065373602"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:00:00Z","timestamp":1760745600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ejca.2025.116062","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T22:25:11Z","timestamp":1760999111000},"page":"116062","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Induction therapy with BRAF\/MEK inhibitors versus upfront ipilimumab\/nivolumab in poor prognostic advanced melanoma"],"prefix":"10.1016","volume":"230","author":[{"given":"M.","family":"Bloem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.J.M.","family":"van den Eertwegh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.B.A.G.","family":"Haanen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.J.B.","family":"Aarts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.W.P.J.","family":"van den Berkmortel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.U.","family":"Blank","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.A.M.","family":"Blokx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.J.","family":"Boers-Sonderen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.D.M.","family":"Boreel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.W.B.","family":"de Groot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.A.P.","family":"Hospers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Kapiteijn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Piersma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Rikhof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.H.J.","family":"Simkens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.M.","family":"Stevense-den Boer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.A.M.","family":"van der Veldt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.W.J.M.","family":"Wouters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.P.M.","family":"Suijkerbuijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2025.116062_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102485","article-title":"Improving survival in advanced melanoma patients: a trend analysis from 2013 to 2021","volume":"69","author":"van Not","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1016\/j.ejca.2025.116062_bib2","doi-asserted-by":"crossref","DOI":"10.1186\/1479-5876-10-85","article-title":"The role of BRAF V600 mutation in melanoma","volume":"10","author":"Ascierto","year":"2012","journal-title":"J Transl Med"},{"issue":"2","key":"10.1016\/j.ejca.2025.116062_bib3","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.22.01763","article-title":"Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF -Mutant melanoma: the DREAMseq trial - ECOG-ACRIN EA6134","volume":"41","author":"Atkins","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2025.116062_bib4","doi-asserted-by":"crossref","DOI":"10.1038\/s41416-020-01229-1","article-title":"First-line BRAF\/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis","volume":"124","author":"van Breeschoten","year":"2021","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2025.116062_bib5","article-title":"Sequencing of immunotherapy and targeted therapy for BRAFV600 mutated melanoma: a retrospective study","volume":"19","author":"Persa","year":"2021","journal-title":"JDDG J Ger Soc Dermatol"},{"key":"10.1016\/j.ejca.2025.116062_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.28620","article-title":"Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors","volume":"120","author":"Ackerman","year":"2014","journal-title":"Cancer"},{"issue":"18","key":"10.1016\/j.ejca.2025.116062_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.2625","article-title":"Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF\/MEK inhibitors, anti-PD-1 antibodies, or nivolumab\/ipilimumab","volume":"8","author":"Moser","year":"2019","journal-title":"Cancer Med"},{"issue":"2","key":"10.1016\/j.ejca.2025.116062_bib8","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.21.02961","article-title":"Sequencing of ipilimumab plus nivolumab and encorafenib plus binimetinib for untreated BRAF -Mutated metastatic melanoma (SECOMBIT): a randomized, Three-Arm, Open-Label phase II trial","volume":"41","author":"Ascierto","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2025.116062_bib9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-Year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ejca.2025.116062_bib10","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.4401","article-title":"Rationale for immune checkpoint inhibitors plus targeted therapy in metastatic melanoma: a review","volume":"6","author":"Dummer","year":"2020","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2025.116062_bib11","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv414","article-title":"Immunotherapy combined or sequenced with targeted therapy in the treatment of solid tumors: current perspectives","volume":"108","author":"Atkins","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2025.116062_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114073","article-title":"Columbus 7-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E\/K-mutant melanoma","volume":"204","author":"Schadendorf","year":"2024","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.ejca.2025.116062_bib13","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx176","article-title":"Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E\/ K-mutant melanoma: long-term survival and safety analysis of a phase 3 study","volume":"28","author":"Long","year":"2017","journal-title":"Ann Oncol"},{"issue":"6286","key":"10.1016\/j.ejca.2025.116062_bib14","article-title":"The \u201ccancer immunogram.\u201d","volume":"352","author":"Blank","year":"2016","journal-title":"Science (1979)"},{"issue":"12","key":"10.1016\/j.ejca.2025.116062_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(16)30578-2","article-title":"Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials","volume":"17","author":"Long","year":"2016","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2025.116062_bib16","doi-asserted-by":"crossref","DOI":"10.1111\/pcmr.12835","article-title":"Switch to checkpoint inhibition after targeted therapy at time of progression or during ongoing response: a retrospective single-centre experience in patients with BRAF-mutated melanoma","volume":"33","author":"Reijers","year":"2020","journal-title":"Pigment Cell Melanoma Res"},{"issue":"12","key":"10.1016\/j.ejca.2025.116062_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11121940","article-title":"Switching to immune checkpoint inhibitors upon response to targeted therapy; the road to long- term survival in advanced melanoma patients with highly elevated serum LDH?","volume":"11","author":"Schouwenburg","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.ejca.2025.116062_bib18","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(25)00133-0","volume":"26","author":"Robert","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.116062_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2016.11.021","article-title":"Dutch melanoma treatment registry: quality assurance in the care of patients with metastatic melanoma in the Netherlands","volume":"72","author":"Jochems","year":"2017","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2025.116062_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin Trials"},{"issue":"3","key":"10.1016\/j.ejca.2025.116062_bib21","doi-asserted-by":"crossref","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivar Behav Res"},{"issue":"2","key":"10.1016\/j.ejca.2025.116062_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/pst.433","article-title":"Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies","volume":"10","author":"Austin","year":"2011","journal-title":"Pharm Stat"},{"issue":"22","key":"10.1016\/j.ejca.2025.116062_bib23","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2000.18.22.3782","article-title":"Prognostic factors in metastatic melanoma: a pooled analysis of eastern cooperative oncology group trials","volume":"18","author":"Manola","year":"2000","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2025.116062_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.33162","article-title":"Real-world outcomes of advanced melanoma patients not represented in phase III trials","volume":"147","author":"van Zeijl","year":"2020","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2025.116062_bib25","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"16_suppl","key":"10.1016\/j.ejca.2025.116062_bib26","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.9522","article-title":"Serum thymidine kinase activity (TKa) as a potential biomarker in the sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma (SECOMBIT) trial","volume":"43","author":"Helgadottir","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925009487?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925009487?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T21:52:25Z","timestamp":1761947545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925009487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":26,"alternative-id":["S0959804925009487"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.116062","relation":{},"ISSN":["0959-8049"],"issn-type":[{"type":"print","value":"0959-8049"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Induction therapy with BRAF\/MEK inhibitors versus upfront ipilimumab\/nivolumab in poor prognostic advanced melanoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.116062","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116062"}}